Journal of Sleep Disorders & Therapy
Open Access

Abstract

Open-Label Observational Study of a Natural Supplement Containing Nootropics and Adaptogenic Mushrooms in Adults Reporting Symptoms Consistent with Chronic Insomnia

Luke Barr MD and Debra Kimless MD*

Background: Sleep disturbances affect up to one-third of adults in the United States and are associated with adverse health and quality-of-life outcomes. Conventional pharmaceutical treatments are often limited by side effects and risk of dependency, prompting interest in well-tolerated, natural alternatives.

Objective: To evaluate the short-term acceptability and efficacy of SensIQ Sleep, a novel supplement containing ashwagandha, valerian root, l-theanine, and reishi mushroom, in adults with chronic insomnia symptoms.

Methods: In this open-label, proof-of-concept study, 38 participants with chronic sleep complaints were enrolled and received weight-based nightly dosing of SensIQ Sleep for 7 days. Sleep quality was assessed before and after the intervention using the PROMIS Sleep Disturbance 8a questionnaire, the Patient Global Impression of Change (PGIC), and a comparison to previously used natural sleep aids.

Results: Participants showed a statistically significant improvement in sleep quality, with PROMIS scores decreasing from a mean of 22.16 (SD=4.22) to 20.47 (SD=2.96) (p=0.027). The median PGIC score was 5.0 (“quite a bit better”), with an interquartile range of 4.0-6.0. Comparison ratings indicated SensIQ Sleep was preferred over prior natural sleep aids (median=4.0; IQR=3.0-5.0). No serious adverse events were reported.

Conclusion: A short course of SensIQ Sleep was well tolerated and associated with meaningful improvements in subjective and validated measures of sleep disturbance. These results support further investigation of this formulation in larger, placebo-controlled trials.

Published Date: 2025-08-05; Received Date: 2025-07-06